Neogen Corp.

NEOGEN CORP

NEOGUSNasdaqHealthcareIn Vitro & In Vivo Diagnostic Substances

Investment brief

Investment brief: Neogen Corp.

Create a free account to read 3 full briefs a month: verdict, strengths, risks, how you could invest and what the price implies. No card needed.

Founding members

The first 100 accounts get 3 months free

98 of 100 free places left · 2 taken

Create your account and get full access for 3 months — no card, no automatic charge. After that it is 20 € a month, only if you choose to continue.

Create a free account

Already have an account? Sign in

Recent signals

Neogen Corp. NEOG

Other disclosure

Regulation FD material, other events or exhibits only; no item that askFlo treats as material.

Other / needs reviewImportance: LowRejected

Neogen Corp. NEOG

Governance matter

Changes to bylaws, shareholder rights or votes; most are administrative.

GovernanceImportance: LowVerified in filing

Recent events →

Key figures · CY2025

Revenue
US$870.4m
Growth
-2.7%
3-year growth (yearly)
+1.9%
Net income
-US$7.9m
Gross margin
46.9%
Operating margin
-2.5%
Net margin
-0.9%
Free cash flow
US$31.9m
Cash
US$145.34m
Long-term debt
US$792.93m
Net cash
-US$647.59m
Dividends + buybacks
—

Four-year trend

Revenue
2022: US$822.45mUS$822.45m20222023: US$924.2m20232024: US$894.7m20242025: US$870.4mUS$870.4m2025
Operating margin
2022: 4.6%4.6%20222023: 6.3%20232024: -118.6%20242025: -2.5%-2.5%2025
Net income
2022: -US$22.87m-US$22.87m20222023: -US$9.4m20232024: -US$1.09bn20242025: -US$7.9m-US$7.9m2025
Operating cash flow
2022: US$41.03mUS$41.03m20222023: US$35.3m20232024: US$58.2m20242025: US$83.2mUS$83.2m2025

Annual figures as reported in each year's 10-K (calendar-aligned years). Operating margin is computed in code as operating income divided by revenue.

Place in every ranking

This company is not in the rankings (they cover companies with at least USD 1 bn in revenue).

Figures for CY2025 (period ending 2026-05-31) from SEC EDGAR XBRL. A dash (—) means the company did not report the figure in a comparable form. These lists rank companies by reported figures. A high rank is a fact about the numbers, not a recommendation to buy, sell or hold, and not personalised advice. Past results do not predict future returns.

Find a company